Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors.
- CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors.
- "Blueprint Medicines' success to date is impressive and the company has a clear, exciting path to achieve its 2027 vision," said Dr. Tsai.
- In addition, the company announced that George D. Demetri, M.D., FASCO, has retired from the Board of Directors and will be joining its Scientific Advisory Board.
- Dr. Tsai joins the Board of Blueprint Medicines with more than 20 years of experience in bringing innovative therapies to market across geographies and therapeutic areas.